Aberdeen Group plc Has $7.23 Million Holdings in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Aberdeen Group plc increased its stake in IDEAYA Biosciences by 43.9% during the first quarter, owning approximately 441,305 shares valued at $7.23 million.
• Several institutional investors, including E Fund Management Co. Ltd. and Russell Investments Group Ltd., also boosted their holdings significantly, indicating strong institutional interest in IDEAYA.
• Analysts have mixed ratings, with most giving IDEAYA a "Moderate Buy" rating and target prices ranging from $25 to $72, reflecting varying outlooks on its stock performance.

Aberdeen Group plc lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 43.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 441,305 shares of the company's stock after acquiring an additional 134,582 shares during the quarter. Aberdeen Group plc owned about 0.50% of IDEAYA Biosciences worth $7,229,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in IDYA. GF Fund Management CO. LTD. acquired a new position in IDEAYA Biosciences in the fourth quarter worth approximately $47,000. CWM LLC grew its position in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its position in IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock worth $39,000 after buying an additional 1,546 shares during the last quarter. Signaturefd LLC grew its position in IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after buying an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in IDEAYA Biosciences by 46.4% in the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after buying an additional 2,112 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 0.6%

Shares of NASDAQ:IDYA traded up $0.15 during trading on Tuesday, reaching $24.86. 589,699 shares of the company traded hands, compared to its average volume of 987,597. The firm has a fifty day simple moving average of $23.08 and a 200 day simple moving average of $20.40. The firm has a market cap of $2.18 billion, a P/E ratio of -6.56 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $40.25.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. During the same period in the previous year, the firm posted ($0.68) earnings per share. The company's revenue was up NaN% compared to the same quarter last year. As a group, research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research report on Thursday, July 10th. JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $48.09.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.